In conclusion, LMB-T20 is a favorable candidate for evaluation in clinical trials due to its reduced immunogenicity and excellent activity. Mol Cancer Ther; 14(12); 2789–96. ©2015 AACR. (Source: Molecular Cancer Therapeutics)
from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=157060569&cid=c_409_6_f&fid=40739&url=http%3A%2F%2Fmct.aacrjournals.org%2Fcgi%2Fcontent%2Fshort%2F14%2F12%2F2789%3Frss%3D1
Reduced Immunogenicity in an Immunotoxin-Targeting Mesothelin
ad
Enregistrer un commentaire